Cancer vaccines

Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Medical specialties, Medicine, Vaccines, Vaccination, Cancer vaccines, Immunology, Antigen, Immune system, Vaccine, Immunogenicity, Individualized cancer immunotherapy

Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.

Key Points: 
  • Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.
  • No significant adverse side effects were reported with the administration of GEN-009, with only mild symptoms associated with the vaccine adjuvant.
  • Title: GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
  • Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time.

Achilles Therapeutics announces formation of Scientific Advisory Board

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Branches of biology, Immune system, Clinical medicine, Cancer treatments, Cancer vaccines, Checkpoint inhibitor, Immune checkpoint, Cancer, Mutanome, Cancer immunotherapy

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Achilles Therapeutics announces formation of Scientific Advisory Board

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Branches of biology, Immune system, Clinical medicine, Cancer treatments, Cancer vaccines, Checkpoint inhibitor, Immune checkpoint, Cancer, Mutanome, Cancer immunotherapy

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Bavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine Program

Retrieved on: 
Wednesday, May 6, 2020
Bavarian Nordic, Severe acute respiratory syndrome-related coronavirus, Vaccine, Vaccines, Biotechnology, Health, Life sciences, Cancer vaccines

Importantly, the production of the vaccine technology can be readily scaled to commercial quantities and AdaptVac is working with AGC Biologics for the manufacture and scale-up of the vaccine.

Key Points: 
  • Importantly, the production of the vaccine technology can be readily scaled to commercial quantities and AdaptVac is working with AGC Biologics for the manufacture and scale-up of the vaccine.
  • Bavarian Nordic will support the consortium to achieve clinical proof of concept and takes responsibility for clinical development and global commercialization of the vaccine.
  • AdaptVac and the PREVENT-nCoV consortium are delighted to have Bavarian Nordic join our SARS-CoV-2 vaccine development efforts.
  • Upon execution of a final license agreement, Bavarian Nordic will make an initial upfront payment to Adaptvac in addition to future development and sales milestones and royalties.

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight

Retrieved on: 
Tuesday, April 28, 2020
Lung cancer, Clinical medicine, Cancer treatments, Medicine, Non-small-cell lung carcinoma, Cancer vaccines, Quinazolines, Primary alcohols, Treatment of lung cancer, Tecemotide

DelveInsight has introduced a newMarket Insights, Epidemiology, and Market ForecastReport on " Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030 " to its portfolio.

Key Points: 
  • DelveInsight has introduced a newMarket Insights, Epidemiology, and Market ForecastReport on " Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030 " to its portfolio.
  • These cases are expected to grow with a significant CAGR in the study period 20172030.
  • The market size of NSCLC in the 7MM is expected to increase during study period.
  • NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight

Retrieved on: 
Tuesday, April 28, 2020
Lung cancer, Clinical medicine, Cancer treatments, Medicine, Non-small-cell lung carcinoma, Cancer vaccines, Quinazolines, Primary alcohols, Treatment of lung cancer, Tecemotide

DelveInsight has introduced a newMarket Insights, Epidemiology, and Market ForecastReport on " Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030 " to its portfolio.

Key Points: 
  • DelveInsight has introduced a newMarket Insights, Epidemiology, and Market ForecastReport on " Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030 " to its portfolio.
  • These cases are expected to grow with a significant CAGR in the study period 20172030.
  • The market size of NSCLC in the 7MM is expected to increase during study period.
  • NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines

Retrieved on: 
Thursday, April 23, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, General Health, Other Science, Science, Oncology, Medicine, Medical specialties, Clinical medicine, Immune system, Immunotherapy, Virotherapy, Adaptive immune system, Immunology, Cancer vaccines

Robert O. Dillman, M.D., chief medical officer at AIVITA, and Gabriel I Nistor, M.D., chief scientific officer at AIVITA, authored the article.

Key Points: 
  • Robert O. Dillman, M.D., chief medical officer at AIVITA, and Gabriel I Nistor, M.D., chief scientific officer at AIVITA, authored the article.
  • The publication provides insight into the innate and adaptive immune responses induced by patient-specific autologous dendritic cell vaccines (DCV) and autologous tumor cell vaccines (TCV), and their impact on survival.
  • DCV was associated with a multipronged innate and adaptive immune response and correlated with improved survival compared to TCV.
  • Cytokine network analysis techniques used to analyze the serologic immune responses generated by each immunotherapy confirmed they triggered differing responses.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Retrieved on: 
Thursday, April 23, 2020
Branches of biology, Medical specialties, Medicine, Cancer vaccines, Vaccines, Vaccination, Genomics, Medical genetics, Vaccine, Immunity, Individualized cancer immunotherapy, Mutanome

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Retrieved on: 
Thursday, April 23, 2020
Branches of biology, Medical specialties, Medicine, Cancer vaccines, Vaccines, Vaccination, Genomics, Medical genetics, Vaccine, Immunity, Individualized cancer immunotherapy, Mutanome

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

BioNTech Announces Full Year 2019 Financial Results and Corporate Update

Retrieved on: 
Tuesday, March 31, 2020
Triple-negative breast cancer, RTT, Breast cancer, Cancer, Health, Clinical medicine, Cancer vaccines

BioNTech is working to initiate clinical testing for BNT162, a potential first-in-class mRNA vaccine against COVID-19, in late April 2020.

Key Points: 
  • BioNTech is working to initiate clinical testing for BNT162, a potential first-in-class mRNA vaccine against COVID-19, in late April 2020.
  • Details of the agreement regarding financial terms and all activities related to the development, manufacturing and potential commercialization are expected to be finalized shortly.
  • BNT114 Data update from a Phase 1 trial in triple negative breast cancer (TNBC) is now expected in 2H 2020.
  • ET (2:00 p.m. CET) to report its financial results for the full year ended December 31, 2019 and provide a corporate update.